This paper provides a comprehensive overview of human papillomavirus (HPV) infections, covering their classification, pathogenesis, and potential new therapies. HPV is a group of over 400 viruses that are among the most prevalent pathogens in humans, causing a significant portion of all cancers and benign lesions. The article discusses the structural and genetic diversity of HPV types, focusing on the role of viral proteins such as E6 and E7 in the development of both benign and cancerous lesions. It highlights the lack of effective drugs to inhibit viral replication and the current treatment methods, which primarily involve lesion removal or immune system stimulation. The paper also explores potential new therapies, including substances that block HPV entry into cells, inhibitors of viral early proteins, and plant-derived substances that inhibit viral replication. Additionally, it reviews the development of prophylactic and therapeutic vaccines, emphasizing the importance of specific immune responses and the challenges in creating effective vaccines. The article concludes by discussing the current state of drug treatments for HPV infections, including topical applications and systemic therapies, and the ongoing research efforts to develop more effective treatments.This paper provides a comprehensive overview of human papillomavirus (HPV) infections, covering their classification, pathogenesis, and potential new therapies. HPV is a group of over 400 viruses that are among the most prevalent pathogens in humans, causing a significant portion of all cancers and benign lesions. The article discusses the structural and genetic diversity of HPV types, focusing on the role of viral proteins such as E6 and E7 in the development of both benign and cancerous lesions. It highlights the lack of effective drugs to inhibit viral replication and the current treatment methods, which primarily involve lesion removal or immune system stimulation. The paper also explores potential new therapies, including substances that block HPV entry into cells, inhibitors of viral early proteins, and plant-derived substances that inhibit viral replication. Additionally, it reviews the development of prophylactic and therapeutic vaccines, emphasizing the importance of specific immune responses and the challenges in creating effective vaccines. The article concludes by discussing the current state of drug treatments for HPV infections, including topical applications and systemic therapies, and the ongoing research efforts to develop more effective treatments.